Group items tagged

Series A pitches have a different emphasis than pitches for later rounds. Improve your presentation by reading this blog post from Common Angels (a Boston-based group of 70 private investors and two co-investment funds under management). The powerpoint template is worth adding to any start-up's collection of resources.

Series A pitches have a different emphasis than pitches for later rounds. Improve your presentation by reading this blog post from Common Angels (a Boston-based group of 70 private investors and two co-investment funds under management). The powerpoint template is worth adding to any start-up's collection of resources.

New Biology Ventures is a life-sciences focused venture capital incubator. They invest in early stage opportunities through the creation and maturation of start-up companies that focus on the development and commercialization of therapeutic biopharmaceuticals. They change the economics of drug development through their unique combination of expertise in finance and structuring companies along with the capability to efficiently and effectively commercialize drugs.

CML HealthCare Inc is planning to automate it's current infrastructure to deliver greater volume and medical laboratory tests. CML is also working to commercialize early-stage technologies in medical diagnostics in partnership with an Ontario government agency known as MaRS Innovation.

MaRS Discovery District announced it has launched a $30-million clean tech fund in collaboration with the private sector.

MaRS Discovery District announced it has launched a $30-million clean tech fund in collaboration with the private sector.

MaRS Discovery District announced it has launched a $30-million clean tech fund in collaboration with the private sector.

"It has been reported that the amount of venture capital invested in Ottawa is slipping. The Venture Capital & Private Equity Association has been observing more early stage companies receiving help from incubators such as MaRS Discovery District in Toronto."

"Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."

"JOLT is MaRS Discovery District's first early-stage accelerator program dedicated to building high-growth web and mobile startups that promise to transform the way consumers and businesses interact with technology."

MaRS Discovery District is expanding. MaRS' Phase 2 development will be completed in 2013. Don Duval, Vice President of Advisory Services states " Our mandate is to work with early stage ventures and help these companies grow ... The program's success, he says, is measured by "the amount of jobs and wealth our companies notable successes.

"Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process."

MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life-sciences technologies during the early stages of pharmaceutical and medical device development.

YouNoodle is a place to discover and support the hottest early-stage companies and university innovation.

The results of the largest study on the financial returns of angel investors in North America were released earlier this week by the Ewing Marion Kauffman Foundation and the Angel Capital Foundation. The study showed that angels affiliated with organized angel groups achieved an average of 27% internal rate of return on their investments. Overall, ".... [these] groups experienced exits that generated 2.6 times their invested capital in 3.5 years from investment to exit. This return compares favorably to that of other private equity investments, including those of early-stage venture capital." In addition to the study's findings on angel investment outcomes, best practices in angel investing were also identified. Areas linked to investment performance were: * due diligence time * industry expertise among investors * active participation by angels in the funded venture * follow-on investing (interestingly, the study found that " ... [i]n ventures where follow-on investments were made, nearly 70 percent of the exits occurred at a loss.")

The Founder Syndrome - Part I Why it's still a big messy issue and why attitudes have to change... It has been debated for years yet remains a small-talk favorite around the water coolers of the venture capital industry. It is "The Founder Syndrome" and it goes something like this… founders innovate, incubate and invigorate. The Founder Syndrome - Part II Avoiding the Deadly Trap Part II looks more closely at the early life-stages of entrepreneurial organizations and the painful transitions associated with the founder syndrome. It argues that by understanding the nature of these transitions, and learning to anticipate, prepare and adapt to them, founders can exert far greater control over their fates while also benefiting the firms they so cherish.

MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries. Dec 15, 2009

This article by David Crane references the Impact Group's paper "Understanding the Disappearance of Early-stage and Start-up R&D Performing Firms" to talk about what's wrong with our innovation/knowledge economy. Among many things, our VC environment is stunted and our businesses should work more closely with customers on addressing their needs rather than focussing on new technology. Read the original white paper at http://www.impactg.com/pdf/disappearanceofstartupsandearlystagefirms.pdf The article also references the paper by the Council of Canadian Academies which urged more business innovation. http://www.scienceadvice.ca/innovation.html

"MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries." Nov 30, 2009

CML HealthCare Inc is planning to automate it's current infrastructure to deliver greater volume and medical laboratory tests. CML is also working to commercialize early-stage technologies in medical diagnostics in partnership with an Ontario government agency known as MaRS Innovation.

"A new convergence of startups and Internet companies has come together to provide other early-stage companies with the tools required to get up and running quickly, and most importantly, cheaply. It's sort of like a Humble Indie Bundle, except instead of gaming, GetStartupTools.com offers software from Wave, Box, MailChimp, Zendesk, Uberflip and General Assembly that most brand new internet companies would need or at least appreciate."